Fulminant myocarditis: Characteristics, treatment, and outcomes

Giacomo Veronese*, Enrico Ammirati*, Manlio Cipriani, Maria Frigerio
“De Gasperis” Cardio Center, Niguarda Hospital; Milan-Italy

Abstract
Myocarditis is an inflammatory disease of the myocardium with a broad spectrum of clinical presentations, ranging from mild symptoms to severe heart failure. The course of patients with myocarditis is heterogeneous, varying from partial or full clinical recovery in few days to advanced low cardiac output syndrome requiring mechanical circulatory support or heart transplantation. Fulminant myocarditis (FM) is a peculiar clinical condition and an acute form of myocarditis, whose main characteristic is a rapidly progressive clinical course with the need for hemodynamic support. Despite the common medical belief of the past decades, recent comprehensive data, including a recent registry that compared FM with acute non-FM, highlighted that FM has a poor inhospital outcome, often requires advanced hemodynamic support, and may result in residual left ventricular dysfunction in survivors. This review aimed to provide an updated practical definition of FM, including essentials in the diagnosis and management of the disease. Finally, the outcome of FM was critically revised according to the current published registries focusing on the topic. (Anatol J Cardiol 2018; 19: 279-86)
Keywords: fulminant myocarditis, mechanical circulatory support, heart transplantation, outcome, registries

Introduction
Myocarditis is an inflammatory disease of the myocardium (1, 2). It often results from common viral infections, through either direct myocyte damage or postviral immune-mediated responses. Myocarditis can also be triggered by nonviral infections and numerous medications, including new immune checkpoint inhibitors (3), and has been associated with several systemic autoimmune disorders (4). Myocarditis has a broad spectrum of clinical presentations, ranging from mild symptoms, such as chest pain associated with minimal ventricular dysfunction, to life-threatening arrhythmia and severe heart failure (HF) (5). Similarly, the course of patients with myocarditis is heterogeneous, varying from partial or full clinical recovery in few days to advanced HF requiring mechanical circulatory support (MCS) or heart transplantation (HTx) (6). The present review was focused on fulminant myocarditis (FM), an acute-onset clinical presentation, whose dramatic presenting scenarios include rapidly progressive hemodynamic compromise, cardiogenic shock, and fatal arrhythmia (7, 8). The main objective of the current review was to provide updated evidence on FM, including a new practical definition, key elements for its diagnosis, controversies in its management, and new insights on its short and long-term course according to recently published series. Particular attention was focused on our recently published registry comparing FM with acute non-FM (6).

Moving toward a modern and practical definition of FM
In 1991, Lieberman et al. (9) defined the clinicopathological scenario of myocarditis. Using clinical and pathological elements, they described FM as follows: acute illness within 2 weeks of the onset of symptoms after a distinct viral prodrome with severe cardiovascular compromise, ventricular dysfunction, and extensive inflammatory infiltrates of lymphocytes and macrophages on histological examination, thus excluding eosinophilic myocarditis and giant cell myocarditis (GCM) that often present with a fulminant course and are clinically undifferentiable. This definition was adopted by McCarthy et al. (10) in their retrospective series of 15 cases with FM, again excluding patients with other inflammatory infiltrates. In a more recent review by Ginsberg et al. (7), FM was defined as the distinct onset of symptoms in the first 2 weeks, followed by severe symptoms of HF and hypotension or overt cardiogenic shock needing inotropes, vasopressors, and/or MCS, thus moving from a clinicopathological entity toward a peculiar clinical scenario for physicians. In our recent study, which included the largest group of patients with FM, key enrollment criteria for FM were the onset of cardiovascular symptoms within 30 days prior to...
admission and low cardiac output syndrome requiring inotropes and/or MCS (6). A suggested practical definition of FM may thus be summarized as follows (Table 1): (1) Acute illness (<2–4-week history from the onset of symptoms); (2) Hemodynamic instability due to cardiogenic shock or arrhythmia (including sudden death); (3) Need for hemodynamic support (inotrope/MCS); and (4) Multiple foci of active myocarditis, regardless of the type of inflammatory infiltrate (i.e., giant cells, granuloma, lymphocytic, or eosinophilic) on histological examination. In summary, FM is not an etiological disease entity, but is a peculiar clinical condition within the acute forms of myocarditis, whose main characteristic is a dramatic and rapidly progressive clinical course.

**Key elements for diagnosis**

FM may affect individuals of all ages, although it is most frequent in the young and pediatric populations. Precise data on the true prevalence or incidence of FM in the general population do not exist. Although defined as an uncommon illness, recent studies have reported myocarditis in up to 12% of cases of sudden death in patients aged <40 years. It is the third leading cause of sudden cardiac death in young competitive athletes (11). In our series of 187 patients with acute myocarditis, FM was diagnosed in 55 (29%) (6). Notably, as the study was carried out in two Italian referral centers for myocarditis and HTx (Niguarda Hospital, Milano and San Matteo Hospital, Pavia), up to 75% of patients with FM were transferred from other hospitals. Early recognition of patients at the risk of progression to fulminant forms is essential. Acute myocarditis evolving into FM generally presents with evidence of systolic dysfunction on echocardiogram, ST-T segment abnormalities on electrocardiogram (ECG), high release of troponins, hypotension, and frequent arrhythmia. A comprehensive approach integrating clinical, imaging, and histological information is pivotal for diagnosis.

**Clinical presentation and initial diagnostic assessment**

Rapidly progressive severe HF symptoms (e.g., dyspnea, peripheral edema, chest discomfort, and worsening fatigue) resulting in hemodynamic compromise and cardiogenic shock and requiring treatment with inotropes or MCS represent the most common clinical presentation (7). Patients are often able to recall a distinct time of the onset of symptoms, usually within the preceding 2–4 weeks. Life-threatening arrhythmia and aborted sudden cardiac death represent the most dramatic clinical presentations. Viral prodromal symptoms (e.g., respiratory or gastrointestinal symptoms) may be found, frequently suggesting postviral etiology, although they can also be present in eosinophilic myocarditis. ECG signs are neither specific nor sensitive. Abnormalities include nonspecific ST segment changes and ST-T elevation mimicking acute coronary syndromes and conduction disturbances. Serum cardiac biomarker levels, specifically for troponin I or T, are usually elevated in myocarditis. Serum inflammatory marker, including leukocyte count, erythrocyte sedimentation rate, and C-reactive protein level, may be elevated, but they lack specificity and sensitivity. Laboratory findings consistent with multi organ failure due to low cardiac output syndrome (e.g., elevated levels of creatinine and liver transaminases) may vary according to the severity of presentation. In our series, dyspnea and syncope, female sex, left bundle-branch block, and life-threatening arrhythmia at presentation were more frequent in FM than in non-FM (6). ECG abnormalities and increase inflammatory and cardiac injury marker levels were common in both the groups.
Coronary angiography is often performed early to exclude acute coronary artery disease. Echocardiography is essential to rule out noninflammatory cardiac diseases and assess global biventricular size and function (12). FM is frequently characterized by severe biventricular dysfunction, a normal-to-mildly increased left ventricle (LV) end-diastolic diameter, increased septal wall thickness reflecting myocardial inflammatory interstitial edema, and presence of pericardial effusion. Regional wall motion abnormalities might be present due to the focal nature of the initial inflammatory process. Cardiac magnetic resonance (CMR) is a useful noninvasive imaging technique as it can detect inflammation, edema, necrosis, and fibrosis within the myocardial tissue (13, 14). However, due to the critical condition of patients with FM in the acute phase, it is often less feasible and frequently delayed and endomyocardial biopsy (EMB) is often performed without CMR. In our series, CMR was performed in 45% of patients with FM within a median time of 15 days since admission. CMR sequences suggestive of edema and late gadolinium enhancement (LGE) were found in all patients with myocarditis. A diffuse LGE pattern was observed more frequently in patients with FM than in those with non-FM patients (80% vs. 20%) (6). LGE is a dynamic time-dependent (inverse correlation with time to first CMR) process in acute myocarditis, mostly reflecting tissue edema in the acute phase (15). A prognostic role of LGE has been described in patients with myocarditis, and variations in guiding treatment and predicting long-term recovery have been highlighted (15).

EMB

EMB is the reference standard for the diagnosis of myocarditis. EMB, when performed in centers with a high-volume experience, has a low complication rate (0%–0.8%) and should thus be practiced in referral centers. Dallas criteria, which are standardized histopathological criteria, are applied to define active myocarditis: an inflammatory infiltration of the myocardium with necrosis of myocytes or borderline myocarditis without myocyte necrosis. Limitations of the Dallas criteria include a high degree of interobserver variability and low sensitivity. Immunohistochemical criteria were introduced to improve its accuracy. Active myocarditis was defined as immunostaining of mononuclear infiltrates (T lymphocytes and macrophages) using a cutoff of >14 cells/mm², in addition to increased expression of HLA class II molecules. Besides the pivotal role in confirming diagnosis, EMB is essential to distinguish specific histologies, such as GCM, eosinophilic myocarditis, and sarcoidosis, from lymphocytic myocarditis, because in the former conditions, early immunosuppressive therapy is recommended, whereas the role of immunosuppressive agents in lymphocytic myocarditis remains controversial (1, 2). Recent scientific statements highly recommend EMB in patients with FM, severe ventricular arrhythmia, or advanced heart block (16-18). EMB should be performed early in the course of the disease, and multiple specimens should be examined to increase the diagnostic accuracy (19). In our series, EMB was performed more frequently in patients with FM than in those with non-FM (71% vs. 8%); 28 patients underwent EMB without CMR, of which 26 had FM (6). Lymphocytic myocarditis was the most frequent form of biopsy-proven myocarditis among FM (72%), followed by GCM (14%), and eosinophilic myocarditis (12%).

Management

Supportive measures and HF medical treatment

Supportive measures play a key role in the management of FM. Initial treatment often requires mechanical ventilation, inotropic agents, and vasopressors to correct hypotension, respiratory failure, and overt cardiogenic shock. In patients with low cardiac output not responding to maximal pharmacological therapy, MCS can be used. Intra-aortic balloon counterpulsation (IABP) has been the most widely used technique to optimize the hemodynamic profile in adults by reducing the afterload and myocardial oxygen demand. When IABP alone is not effective in maintaining adequate cardiac output, several temporary MCS devices can be employed (20). Among MCS devices, venoarterial extracorporeal membrane oxygenator (va-ECMO) has been the most extensively used advanced temporary MCS device in recent years for providing cardiorespiratory support in seriously ill patients and often represents the unique MCS suitable for pediatric patients. Indeed, in 2005, Asaumi et al. (21) described one of the first series of patients (n=14) with FM treated with percutaneous va-ECMO in Japan from 1996 and 2001. They found that va-ECMO could be useful to increase survival in patients with FM, observing a 71% inhospital survival, thus demonstrating the advantage of using va-ECMO in refractory FM. The published va-ECMO weaning rates due to cardiac recovery in FM ranged from 66% to 100%, with a survival to hospital discharge ranging from 56% to 87.5%, including data from Extracorporeal Life Support Organization (ELSO) (21-35). In our series, MCS was used in 65% of patients (70% of adults and 25% of pediatric patients); IABP was the most commonly used MCS device, alone or in combination with va-ECMO. The overall inhospital survival was 74.5%, which was consistent with previous similar registries. Long-term implantable left ventricle assist devices (LVADs) are rarely used to provide adequate circulation for a more extended time period to allow the resolution of myocarditis and bridge a patient from emergent temporary MCS to HTx, which is the final option for treating critically ill patients affected by myocarditis. HTx survival is comparable to that of patients with other types of HF as shown in a recent series, although higher rates of relapses have been demonstrated, especially in patients with GCM undergoing HTx (36, 37). Once patients with FM recover from cardiogenic shock, pharmacological treatment for HF, including beta-blockers, diuretics, angiotensin-converting enzyme inhibitors or angiotensin-II receptor blockers, should be initiated according to current consensus (38).

Immunosuppressive treatment

Immunosuppressive therapy is the mainstay of treatment for eosinophilic myocarditis, GCM, cardiac sarcoidosis, and FM forms of pericarditis as a last-resort therapy. First-line drugs include corticosteroids, azathioprine, mycophenolate mofetil, and cyclosporine. Azathioprine, mycophenolate mofetil, and cyclosporine are usually administered as monotherapy or in combination for 12–24 months.
associated with systemic autoimmune diseases (39-41). Since the first report of the Multicenter GCM Study Group, recommend-
ed treatment has been the triple combination of antithymocyte
globulins, prednisone, and cyclosporine (42). Other available im-
munosuppressants, such as intravenous immunoglobulins (mostly
used in pediatric patients), mycophenolate mofetil, methotrexate,
rituximab, or azathioprine, can be included or used as second-line
treatments (43). In our center, GCM is treated with initial high-dose
steroids whose dose is gradually tapered (e.g., methylprednisolone
1000 mg once a day for 3 days, followed by prednisone 60 mg once
a day for 15 days and finally tapered to 10 mg once a day for 6–10
weeks), plus thymoglobulin (1 mg/kg, generally as a single dose),
and cyclosporine (5 mg/kg a day, continued long-term). In case of
eosinophilic myocarditis, steroids (e.g., methylprednisolone 1000
mg once a day for 3 days, followed by oral prednisone 1 mg/kg once
a day with gradual tapering) are advocated (41, 44). Use of other
immunosuppressants has also been reported (e.g., azathioprine 2
mg/kg or intravenous cyclophosphamide) (41). Withdrawal of pos-
sible etiologically relevant drugs is mandatory in case of suspected
hypersensitivity or evidence of hypereosinophilia. First-line treat-
ment of cardiac sarcoidosis includes either intravenous adminis-
tration of corticosteroid alone or in combination with azathioprine
or methotrexate (45), whereas cyclophosphamide or rituximab
can be used in unresponsive forms. Immunosuppressants are also
recommended in myocarditis associated with systemic immune
diseases (18). Currently, there is a complete lack of standardized
immunosuppressive management for lymphocytic postviral FM,
and its role remains controversial (16, 46). Current evidence mostly
obtained from a cohort of patients with myocarditis and chronic
HF (>6 months) suggested that in patients with lymphocytic myocar-
ditis, immunosuppressive treatment should be administered only in
the presence of elevated levels of tissue inflammatory markers and
absence of a viral genome on PCR analyses of myocardial samples
(40). However, the importance of the presence of viral genome in
guiding the treatment for acute-phase FM is currently unknown.
Current recommendations of our center include intravenous gam-
maglobulin administration in pediatric patients (single-infusion
regimen of 0.5–2 g/kg) and steroid administration in adults (e.g.,
methylprednisolone 1000 mg once a day for 3 days, followed by oral
prednisone 1 mg/kg once a day with gradual tapering). In our
series, a large proportion of patients with FM were treated with im-
munosuppressive therapy (overall 64%, regimens including the use
of intravenous steroids in 43% and steroids alone in 30%); when
considering only adults with postviral myocarditis, overall 55% of

| Table 2. Registries including cases of fulminant myocarditis |
|---------------------------------|------------|--------|-----------|------------|---------------|-------------|
| Authors                        | Years      | Patients | Age       | LVEF at admission | Histology | Treatment | Duration of follow-up | Events       |
| Lieberman et al. 1991 (9)      | 12/1983-07/1988 | 4       | -         | -               | All lymphocytic | -            | 4.7 y | 1 death | 0 HTx |
| McCarthy et al. 2000 (10)      | 7/1984-6/1997 | 15      | 35±16 y   | -               | All lymphocytic | 2 MCS       | 5.3 y (15 d-11 y) | 1 death | 0 HTx |
| Amabile et al. 2006 (47)       | 1998-2003   | 11      | 1 y (0-9) | 22±9%           | Available in 3 patients History ns | 13 vasopressors 0 MCS 0 | 9 inotropes | 58.7 m (33.8-83) | 1 death |
| Teele et al. 2011 (48)         | 1996-2008   | 20      | 12.7 y    | 27.8% (8-55)    | Available in 18 patients History ns | 10 MCS       | 0.7 y (13 d-6.4 y) | 3 deaths | 1 HTx |
| Matsuura et al. 2016 (49)      | 01/2006-12/2011 | 74     | 6.5±5.3 y | -               | -            | 51 MCS      | -            | 38 death |
| Anzini et al. 2013 (50)        | 1981-2009   | 10      | 28±18 y   | 22% (18-24)     | 9 lymphocytic 1 eosinophilic Available in 43 patients | 5 MCS         | 147 m±107 | 5 deaths or HTx |
| Ammirati et al. 2017 (6)       | 05/2001-11/2016 | 55     | 33 y (17-42) | 22% (18-30) | 5 eosinophilic Available in 32 lymphocytic 7 GCM | 5 eosinophilic      | 55 inotropes | 59 m (29-83) | 10 deaths | 5 HTx |
| Inaba et al. 2007-2009         | 42         | -       | 31±16%    | -               | -            | 37 MCS      | -            | 20 deaths |

GCM - giant cell myocarditis; HTx - heart transplantation; LVEF - left ventricle ejection fraction; MCS - mechanical circulatory support; ns - not specified

*Histological data available either from endomyocardial biopsy or autopsy specimen

*Pediatric patients only
patients were treated with immunosuppressive therapy, including intravenous steroids in 45% and steroids alone in 39% (6).

**Favorable or unfavorable outcomes?**
Careful evaluation of the patient population and study inclusion criteria used to define FM series is essential when studying short- and long-term FM outcomes (Table 2). In 1991, Lieberman et al. (9) were the first to describe four cases of FM. Full recovery of LV function (in three patients) or death from the disease (one of four) within 1 month was considered one of the five characteristics distinguishing FM from non-FM. Limitations of their series were the small number of cases and the fact that only patients with lymphocytic myocarditis were included. McCarthy et al. (10) subsequently published a retrospective series of 15 FM cases and compared them with patients with acute non-FM with reduced LV function. All patients with FM were defined as having fever, distinct onset of HF symptoms, history consistent with the presence of a viral illness within 2 weeks before hospitalization, histopathologically borderline or active myocarditis on EMB, and severe hemodynamic compromise requiring high doses of vasopressors or LVAD. In this series, two patients with FM required MCS; the remaining received high-dose vasopressors. Among the patients with FM, only one died during index hospitalization, and 93 percent were alive without having received HTx at 1 year and at the end of 11 years, showing that patients with FM, despite the critical illness at presentation, have excellent long-term survival, which is distinct from that of patients with acute myocarditis. Study limitations include the low number of FM cases, exclusion of GCM or eosinophilic myocarditis, absence of autopsy cases, and longer time frame between symptom onset and study inclusion, possibly contributing to a selection bias. Besides, patients with FM could have been underrepresented, because in the study period (1984–1997), temporary MCS was less extensively used, possibly leading to exclusion of severe FM cases dying prior to study enrollment due to rapid unfavorable disease course. With the advent of MCS, the chance of survival for severe FM presenting with refractory cardiogenic shock has increased, and several studies enrolling FM cases aggressively treated with MCS have highlighted their poor inhospital survival, better reflecting the life-threatening course of the disease (47-50). Anzini et al. (50) studied 10 biopsy-proven FM cases; of these, four (40%) were aged <13 years. Histopathological analysis identified lymphocytic myocarditis in nine patients and eosinophilic myocarditis in one patient. An additional five patients had histopathologically active myocarditis and eosinophilic myocarditis, respectively, and one each had GCM and lymphocytic myocarditis.

**Table 3. Studies including 10 or more patients with fulminant myocarditis managed by extracorporeal circulatory support**

| Authors                  | Years               | Patients | Age          | Histology* | Survival to hospital discharge |
|--------------------------|---------------------|----------|--------------|------------|-------------------------------|
| Aoyama et al. 2002 (22)  | 05/1989-03/2000     | 52       | 47.9±16 y    | Available in 43 patients  
Lymphocytic ns  
2 eosinophilic 2 GCM | 59.6% |
| Chen et al. 2005 (25)    | 1994-2001           | 15       | 27.1±19.3 y  | Available in 11 patients  
10 lymphocytic 1 GCM   | 73%  |
| Asaumi et al. 2005 (21)  | 1/1993-12/2001      | 14       | 17±2 y       | Available in 9 patients  
Histology ns           | 71.4%|
| Thiaagarajan et al. 2009 (26)| 1992-2007           | 16       | -            | -                             | 56% |
| Gariboldi et al. 2010 (27)| 03/2006-06/2008     | 10       | -            | -                             | 70% |
| Hsu et al. 2011 (24)     | 1994-2009           | 75       | 29.7±18.7 y  | Available in 50 patients  
Histology ns           | 64% |
| Ishida et al. 2013 (28)  | 01/1995-03/2010     | 20       | 45.1±19.2 y  | -                             | 60% |
| Mirabel et al. 2011 (30) | 01/2002-03/2009     | 35       | -            | Available in 25 patients  
20 lymphocytic 2 GCM 2 eosinophilic | 68.6%|
| Beurtheret et al. 2013 (31)| 01/2005-12/2009     | 14       | -            | -                             | 65% |
| Wu et al. 2012 (33)      | 01/2003-06/2010     | 16       | -            | -                             | 87.5%|
| Diddle et al. 2015 (32)  | 1995-2011           | 147      | 31 y (21-47) | -                             | 61% |
| Nakamura et al. 2015 (29)| 1999-2013           | 22       | Survivor g: 36.5±4.1 y  
Non survivor g: 60.2±5 y | -                             | 59% |
| Lorusso et al. 2016 (34) | 01/2008-12/2013     | 57       | 37.6±11.8 y  | Available in 15 patients  
Histology ns           | 71.9%|
| Inaba et al. 2017 (35)   | 2007-2009           | 37       | -            | -                             | 59% |

GCM - giant cell myocarditis; ns - not specified
*Histological data available either from endomyocardial biopsy or autopsy specimen
Fulminant myocarditis is a severe inflammatory disease of the myocardium presenting with dramatic clinical scenarios, including fatal ventricular arrhythmia and rapidly progressive severe HF resulting in hemodynamic compromise that often requires treatment with inotropes or MCS. Despite the common medical belief of the past decades, recent strong and comprehensive data highlight that treatment in an early stage of the disease, death or need for HTx is more common in FM, both in adults with myocarditis with cardiogenic shock and highlighting the high inhospital mortality of this disease. In conclusion, if a specific treatment (e.g., steroids) is initiated, the greatest benefit should be expected in the initial weeks from onset of the disease, and is characterized by partial long-term survival have been provided. In our recent study, inhospital mortality was 18.2% (10 deaths) in patients with FM compared with 0% in those with non-FM (6). Death or HTx occurred in 25.5% (10 deaths and 4 HTx) and 0%, respectively. HTx-free survival was significantly reduced in FM compared with non-FM at the 9-year follow-up (64.5% vs. 100%). In the FM group, most adverse events occurred during hospitalization: 10 deaths (all from cardiac causes), four HTxs, and one LVAD implantation who underwent HTx within 1 year. Among the 10 inhospital deaths, one had GCM, two had eosinophilic myocarditis, and seven had lymphocytic myocarditis. Four transplanted patients had GCM, and one patient discharged on LVAD had lymphocytic myocarditis. When only verified cardiac deaths were considered, worse survival for FM compared with non-FM at the 9-year follow-up (74.9% vs. 100%) was still present. Moreover, when children were excluded, HTx-free survival was significantly reduced in FM compared with that in non-FM (63.8% vs. 100%). Similar findings were obtained in subanalysis that focused on adult patients with acute postviral myocarditis. Confirming the significantly higher mortality and need for HTx previously observed in pediatric patients with FM (49), we had three inhospital deaths among the eight pediatric patients with FM (all lymphocytic myocarditis). Consistent with previous reports, no cardiac deaths occurred in our patients with FM and non-FM after the acute phase. LVEF improved in both FM and non-FM groups during hospitalization, although LVEF at discharge was significantly lower in patients with FM than in those with non-FM. The proportion of patients with LVEF of <55% at discharge was larger in the FM than in the non-FM group (53% vs. 19%). Considering the last available LVEF after discharge with a median follow-up of 22 months, the proportion of patients with LVEF of <55% was still higher in the FM group than in the non-FM group (29% vs. 9%). Most LVEF recovery was observed during hospitalization, with a median increase in LVEF of 32% in patients with FM. Thus, if a specific treatment (e.g., steroids) is initiated, the greatest benefit should be expected in the initial weeks from onset, when the greatest recovery has been observed. In conclusion, at odds with initial findings, recent evidence underline that FM is associated with high inhospital mortality and need for HTx, mostly in the acute phase of the disease, and is characterized by partial long-term LV functional recovery in a significant group of patients.

Conclusion

FM is a severe inflammatory disease of the myocardium presenting with dramatic clinical scenarios, including fatal ventricular arrhythmia and rapidly progressive severe HF resulting in hemodynamic compromise that often requires treatment with inotropes or MCS. Despite the common medical belief of the past decades, recent strong and comprehensive data highlight that FM has poor inhospital outcome and often requires proper monitoring in intensive care unit and prolonged hemodynamic support with inotropes and temporary MCS. Especially in the acute phase of the disease, death or need for HTx is more common in FM, both...
for relatively rare forms with high mortality (i.e., GCM or eosinophilic myocarditis) as well as for less lethal forms (e.g., lymphocytic myocarditis), than in non-FM. Moreover, patients with FM have more severely impaired LVEF at admission, which despite steep improvements during hospitalization, remains lower than that in patients with non-FM at long-term follow-up, suggesting partial LV healing. To reduce inhospital mortality rates, rapid referral to hub centers for aggressive supportive treatment and early EMB should be the standard of care for FM in the modern era. Although in specific forms of FM (i.e., eosinophilic myocarditis, GCM, cardiac sarcoidosis), immunosuppressive therapy represents the mainstay of medical treatment, there is a complete lack of standardized medical management for lymphocytic FM despite the increasing evidence of its poor outcome. A critical re-evaluation of the role of immunosuppressive treatment in the acute phase of lymphocytic FM is warranted in order to further improve inhospital survival and prevent irreversible myocardial injury.

Conflict of interest: None declared.

Peer-review: Externally peer-reviewed.

Authorship contributions: Concept – G.V., E.A., M.C., M.F.; Design – G.V., E.A.; Supervision – E.A., M.C., M.F.; Analysis &/or interpretation - G.V., E.A., M.C., M.F.; Literature search – G.V., E.A., M.C., M.F.; Writing – G.V., E.A.; Critical review – G.V., E.A., M.C., M.F.

References

1. Cooper LT Jr. Myocarditis. N Engl J Med; 360: 1526-38. [CrossRef]
2. Sagar S, Liu PP, Cooper LT Jr. Myocarditis. Lancet 2012; 379: 738-47. [CrossRef]
3. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant Myocarditis With Combination Immune Checkpoint Blockade. N Engl J Med 2016; 375: 1749-55. [CrossRef]
4. Elamm C, Fairweather D, Cooper LT. Pathogenesis and diagnosis of myocarditis. Heart 2012; 98: 835-40. [CrossRef]
5. Sinagra G, Anzini M, Pereira NL, Bussani R, Finocchiaro G, Bar- tunek J, et al. Myocarditis in Clinical Practice. Mayo Clin Proc 2016; 91:1256-66. [CrossRef]
6. Ammirati E, Cipriani M, Lilliu M, Sormani P, Varretti M, Raineri C, et al. Survival and Left Ventricular Function Changes in Fulminant Versus Nonfulminant Acute Myocarditis. Circulation 2017; 136: 529-45.
7. Ginsberg F, Parrillo JE. Fulminant myocarditis. Crit Care Clin 2013; 29: 465-83. [CrossRef]
8. Gupta S, Markham DW, Drazner MH, Mammen PP. Fulminant myocarditis. Nat Clin Pract Cardiovasc Med 2008; 5:693-706. [CrossRef]
9. Lieberman EB, Hutchins GM, Herskowitz A, Rose NR, Baughman KL. Clinicopathologic description of myocarditis. J Am Coll Cardiol 1991; 18: 1617-26. [CrossRef]
10. McCarthy RE, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Hare JM, et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000; 342: 690-5. [CrossRef]
11. Harmon KG, Asif IM, Maleszewski JJ, Owens DS, Prutkin JM, Salerno JC, et al. Incidence, Cause, and Comparative Frequency of Sudden Cardiac Death in National Collegiate Athletic Association Athletes: A Decade in Review. Circulation 2015; 132: 10-9. [CrossRef]
12. Felker GM, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Baughman KL, et al. Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol 2000; 36: 227-32. [CrossRef]
13. Kramer CM, Barkhausen J, Flammm SD, Kim RJ, Nagel E, Society for Cardiovascular Magnetic Resonance Board of Trustees Task Force on Standardized Protocols. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. J Cardiovasc Magn Reson 2013; 15: 91. [CrossRef]
14. Lurz P, Luecke C, Eitel I, Föhrenbach F, Frank C, Grothoff M, et al. Comprehensive Cardiac Magnetic Resonance Imaging in Patients With Suspected Myocarditis: The MyoRacer-Trial. J Am Coll Cardiol 2016; 67: 1800-11. [CrossRef]
15. Ammirati E, Moroni F, Sormani P, Peritore A, Milazzo A, Quattrocchi G, et al. Quantitative changes in late gadolinium enhancement at cardiac magnetic resonance in the early phase of acute myocarditis. Int J Cardiol 2017; 231: 216-21. [CrossRef]
16. Luyt CE, Hekimian G, Ginsberg F. What’s new in myocarditis? Intensive Care Med 2016; 42: 1055-7. [CrossRef]
17. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. Eur Heart J 2007; 28: 3076-93. [CrossRef]
18. Cafferio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, et al; European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34: 2636-48. [CrossRef]
19. Leone O, Veinot JP, Angelini A, Baandrup UT, Basso C, Berry G, et al. 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol 2012; 21: 245-74.
20. Reytovitch A, Barghash MH, Hochman JS. Management of refractory cardiogenic shock. Nat Rev Cardiol 2016; 13: 481-92. [CrossRef]
21. Asaumi Y, Yasuda S, Morii I, Kakuchi H, Otsuka Y, Kawamura A, et al. Favourable clinical outcome in patients with cardiogenic shock due to fulminant myocarditis supported by percutaneous extracorporeal membrane oxygenation. Eur Rev Cardiol 2016; 13: 2165-92. [CrossRef]
22. Aoyama N, Izumi T, Hiramoto K, Isobe M, Kawana M, Hiroe M, et al. National survey of fulminant myocarditis in Japan: therapeutic guidelines and long-term prognosis of using percutaneous cardio-pulmonary support for fulminant myocarditis (special report from a scientific committee). Circ J 2002; 66: 133-44. [CrossRef]
23. Cheng R, Hachamovitch R, Kittleson M, Patel J, Arabia F, Moriguchi J, et al. Clinical outcomes in fulminant myocarditis requiring extracorporeal membrane oxygenation: a weighted meta-analysis of 170 patients. J Card Fail 2014; 20: 400-6. [CrossRef]
24. Hsu KH, Chi NH, Yu HY, Wang CH, Huang SC, Wang SS, et al. Extracorporeal membrane oxygenation support for acute fulminant myocarditis: analysis of a single center’s experience. Eur J Cardio-thorac Surg 2011; 40: 682-8. [CrossRef]
25. Chen YS, Yu HY, Huang SC, Chiu KM, Lin TY, Lai LP, et al. Experience and result of extracorporeal membrane oxygenation in treating fulminant myocarditis with shock: what mechanical support should be
considered first? J Heart Lung Transplant 2005; 24: 81-7. [CrossRef]

26. Thiagarajan RR, Brogan TV, Scheuer MA, Laussen PC, Rycus PT, Bratton SL. Extracorporeal membrane oxygenation to support cardiopulmonary resuscitation in adults. Ann Thorac Surg 2009; 87: 778-85. [CrossRef]

27. Gariboldi V, Grisoli D, Tarmiz A, Juassaun N, Chalvignac V, Kerbaul F, et al. Mobile extracorporeal membrane oxygenation unit expands cardiac assist surgical programs. Ann Thorac Surg 2010; 90: 1548-52. [CrossRef]

28. Ishida K, Wada H, Sakakura K, Kubo N, Sugawara Y, et al. Long-term follow-up on cardiac function following fulminant myocarditis requiring percutaneous extracorporeal cardiopulmonary support. Heart Vessels 2013; 28: 86-90. [CrossRef]

29. Nakamura T, Ishida K, Taniguchi Y, Seguchi M, Wada H, et al. Prognosis of patients with fulminant myocarditis managed by peripheral venoarterial extracorporeal membranous oxygenation support: a retrospective single-center study. J Intensive Care 2015; 3: 5. [CrossRef]

30. Mirabel M, Luyt CE, Leprince P, Trouillet JL, Leger P, Pavie A, et al. Outcomes, long-term quality of life, and psychologic assessment of fulminant myocarditis patients rescued by mechanical circulatory support. Crit Care Med 2011; 39: 1029-35. [CrossRef]

31. Beutheret S, Mordant P, Paoletti X, Marijon E, Celermajer DS, Leger P, et al. Mobile extracorporeal membrane oxygenation for 21 days. J Heart Vessels 2013; 101: 112-20. [CrossRef]

32. Diddle JW, Almodovar MC, Rajagopal SK, Rycus PT, Thiagarajan RR. Extracorporeal membrane oxygenation for the support of adults with acute myocarditis. Crit Care Med 2015; 43: 1016-25. [CrossRef]

33. Wu MY, Lee MY, Lin CC, Chang YS, Tsai FC, Lin PJ. Resuscitation of non-cardiomyopathy cardiogenic shock patients or cardiac arrest with extracorporeal life support: the role of bridging to intervention. Resuscitation 2012; 83: 976-81. [CrossRef]

34. Lorusso R, Centofanti P, Gelsomino S, Barili F, Di Mauro M, Orlando P, et al. Venoarterial Extracorporeal Membrane Oxygenation for Acute Fulminant Myocarditis in Adult Patients: A 5-Year Multi-Institutional Experience. Ann Thorac Surg 2016; 101: 919-26. [CrossRef]

35. Inaba K, Satoh Y, Isobe M, Yamamoto T, Nagao K, Takayama M. Factors and values at admission that predict a fulminant course of acute myocarditis: data from Tokyo CCU network database. Heart Vessels 2017; 32: 952-9. [CrossRef]

36. ElAmm CA, Al-Kindi SG, Oliveira GH. Characteristics and Outcomes of Patients With Myocarditis Listed for Heart Transplantation. Circ Heart Fail 2016; 9: e003259. [CrossRef]

37. Ting M, Wang CH, Tsao CI, Huang SC, Chi NH, Chou NK, et al. Heart Transplantation Under Mechanical Circulatory Support for Acute Fulminant Myocarditis With Cardiogenic Shock: 10 Years’ Experience of a Single Center. Transplant Proc 2016; 48: 951-5. [CrossRef]

38. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 919-957. [CrossRef]

39. Schultheiss HP, Kuhl U, Cooper LT. The management of myocarditis. Eur Heart J 2011; 32: 2616-25. [CrossRef]

40. Frustaci A, Chimenti C. Immunosuppressive therapy in myocarditis. Circ J 2015; 79: 4-7. [CrossRef]

41. Brambatti M, Matassini MV, Adler ED, Klingel K, Camici PG, Ammirati E. Eosinophilic Myocarditis: Characteristics, Treatment, and Outcomes. J Am Coll Cardiol. 2017; 70: 2363-75. [CrossRef]

42. Cooper LT Jr, Hare JM, Tazelaar HD, Edwards WD, Starling RC, Deng MC, et al. Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol 2008; 102: 1535-9. [CrossRef]

43. Ammirati E, Oliva F, Belli O, Bonacina E, Pedrotti P, Turazza FM, et al. Giant cell myocarditis successfully treated with antithymocyte globulin and extracorporeal membrane oxygenation for 21 days. J Cardiovasc Med (Hagerstown) 2016; 17 (Suppl 2): e151-3. [CrossRef]

44. Ammirati E, Stuchi M, Brambatti M, Spano F, Bonacina E, Recalcati F, et al. Eosinophilic myocarditis: a paraneoplastic event. Lancet. 2015; 385: 2546. [CrossRef]

45. Blauwet LA, Cooper LT. Idiopathic giant cell myocarditis and cardiac sarcoidosis. Heart Fail Rev 2013; 18: 733-46. [CrossRef]

46. Heymans S, Eriksson U, Lehtonen J, Cooper LT Jr. The Quest for New Approaches in Myocarditis and Inflammatory Cardiomyopathy. J Am Coll Cardiol 2016; 68: 2348-64. [CrossRef]

47. Amabile N, Fraisse A, Bouvenot J, Chetaille P, Ovaert C. Outcome of acute fulminant myocarditis in children. Heart 2006; 92: 1269-73. [CrossRef]

48. Teele SA, Allan CK, Laussen PC, Newburger JW, Gauvreau K, Thiagarajan RR. Management and outcomes in pediatric patients presenting with acute fulminant myocarditis. J Pediatr 2011; 158: 638-43. [CrossRef]

49. Matsuura H, Ichida F, Saji T, Ogawa S, Waki K, Kaneko M, et al. Clinical Features of Acute and Fulminant Myocarditis in Children-2nd Nationwide Survey by Japanese Society of Pediatric Cardiology and Cardiac Surgery. Circ J 2016; 80: 2362-8. [CrossRef]

50. Anzini M, Merlo M, Sabbadini G, Barbati G, Finocchiaro G, Pianmonti B, et al. Long-term evolution and prognostic stratification of biopsy-proven active myocarditis. Circulation 2013; 128: 2384-94. [CrossRef]